Thallion attempts to tame Jaguar ahead of Bellus acquisition vote
This article was originally published in Scrip
Canadian firm Thallion Pharmaceuticals will hold a shareholder meeting on 6 August to vote on the proposed acquisition of Thallion by Bellus Health. Thallion's board is keen for the deal to proceed, but its largest single shareholder, Jaguar Financial which holds 10.1%, has indicated it will vote against the deal unless terms are increased.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.